GAGA Share Market News

[hfe_template id='11223'] [ad_1] Sagility India’s shares hit a 5% upper circuit, rising to Rs 52.6 on Thursday’s trade at BSE, following the company’s strong Q3 results. The healthtech services provider reported a 207.2% year-on-year (YoY) jump in its net profit for Q3FY25, posting Rs 217 crore, compared to Rs 70.6 crore in the same quarter last year. The company's revenue from operations in the December 2024 quarter grew by 15.3%, reaching Rs 1,453 crore, up from Rs 1,260 crore in the corresponding period of the previous fiscal year. EBITDA for Q3FY25 surged 50.7% to Rs 391.8 crore from Rs 260 crore YoY, while the EBITDA margin expanded to 27% from 20.6%. “Q3FY25 was an exceptional quarter both in terms of top-line and bottom-line, driven by growth both in our tenured large clients as well as newer accounts which we won in the last three years. Our acquisition of BroadPath diversifies our client base and adds new capabilities to our already broad and deep service po...

[hfe_template id='11223'] [ad_1] Sagility India shares jumped another 5% on Thursday to hit a fresh high of Rs 51.35, rallying for the 8th consecutive day. The stock is now up 61% in the last month, while the Sensex has lost nearly 2% of its value. Earlier in the week, global brokerage firm JPMorgan initiated coverage on Sagility with an "Overweight" rating and a target price of Rs 54. Sagility India Share Price Target JPMorgan highlighted Sagility's strong positioning in the niche healthcare services segment, primarily catering to non-discretionary spending, which provides a stable growth outlook even in uncertain market conditions. JPMorgan emphasized that Sagility is well-positioned to benefit from secular tailwinds, particularly due to the increasing trend of outsourcing in the US healthcare sector. As healthcare providers look to reduce costs and enhance efficiency, Sagility’s offerings have become critical, solidifying its role as a dependable outsour...

[hfe_template id='11223'] [ad_1] Shares of Sagility India soared by 5% to hit the upper circuit of Rs 48.91 on the BSE after the global brokerage firm JPMorgan initiated coverage on the stock with an "Overweight" rating and a target price of Rs 54. The target price indicates a potential for 16% upside in the stock from its closing price on Monday. The brokerage highlighted Sagility's strong positioning in the niche healthcare services segment, catering largely to non-discretionary spending, which provides a stable growth outlook even in uncertain market conditions. JPMorgan emphasized that Sagility is well-placed to benefit from secular tailwinds, particularly due to the increasing trend of outsourcing in the US healthcare sector. As healthcare providers look to reduce costs and enhance efficiency, Sagility’s offerings have become critical, cementing its role as a dependable outsourcing partner. “The company’s deep domain expertise and longstanding client r...

[hfe_template id='11223'] [ad_1] Shares of Sagility India surged 9.6% to an intraday high of Rs 32.90 on the BSE after listing on the bourses on Tuesday. The stock debuted on the BSE at Rs 31.06, a premium of 3.5% over its upper price band of Rs 30. The stock opened at the same price on the NSE as well. Sagility India shares opened slightly above the market expectation of merely Rs 0.3 per share. The company made a decent debut on the stock market and the IPO received a moderate subscription of 3.2 times. The listing performance is considered positive given the company's specific focus on the US healthcare market, which is subject to various regulatory and economic factors. “Investors should remain cautious. The company's reliance on a single market and the potential impact of US policy changes could pose risks. Additionally, the high valuation and the nature of the IPO as a complete offer for sale (OFS) may limit upside potential,” said Shivani Nyati, Head of We...